Lupin gains on launching Raltegravir Tablets
Lupin is currently trading at Rs. 2031.00, up by 19.00 points or 0.94% from its previous closing of Rs. 2012.00 on the BSE.
The scrip opened at Rs. 2025.00 and has touched a high and low of Rs. 2061.55 and Rs. 2013.80 respectively. So far 18676 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2530.00 on 16-Jul-2026 and a 52 week low of Rs. 1893.25 on 23-Oct-2026.
Last one week high and low of the scrip stood at Rs. 2,061.55 and Rs. 1,964 respectively. The current market cap of the company is Rs. 93516.42 crore.
The promoters holding in the company stood at 46.84%, while Institutions and Non-Institutions held 47.06% and 6.09% respectively.
Lupin has launched Raltegravir Tablets USP, 600 mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application. Raltegravir Tablets, 600 mg are bioequivalent to the reference listed drug (RLD) Isentress HD Tablets, 600 mg of Merck Sharp & Dohme, LLC. and indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adult patients and in pediatric patients weighing at least 40 kg. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.
Raltegravir Tablets USP, 600 mg (RLD Isentress HD) had an estimated annual sale of $26 million in the U.S.
